Advanced Periocular Basal Cell Carcinoma with Orbital Invasion: Update on Management and Treatment Advances

被引:0
|
作者
Bengoa-Gonzalez, Alvaro [1 ]
Mencia-Gutierrez, Enrique [1 ]
Garrido, Maria [2 ]
Salvador, Elena [3 ]
Lago-Llinas, Maria-Dolores [1 ]
机构
[1] Univ Complutense Madrid, Octubre Hosp 12, Ophthalmol Dept, Madrid, Spain
[2] Univ Complutense Madrid, Octubre Hosp 12, Dept Pathol, Madrid, Spain
[3] Univ Complutense Madrid, Octubre Hosp 12, Radiol Dept, Madrid, Spain
关键词
HEDGEHOG PATHWAY INHIBITION; LABEL CLINICAL-TRIAL; PERINEURAL INVASION; MALIGNANT-TUMORS; SKIN-CANCER; EXENTERATION; VISMODEGIB; EXCISION; RISK; RECONSTRUCTION;
D O I
10.1155/2024/4347707
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. Basal cell carcinoma (BCC) is the most frequent malignant periocular tumor. It is associated with exposure to ultraviolet radiation, and its incidence is gradually increasing. It may occasionally display more aggressive behavior and result in orbital or intracranial invasion. Mortality from periocular BBC with orbital invasion is very low, but the associated morbidity can be significant, from disfigurement to blindness. Traditionally, these cases have been treated with orbital exenteration or with radiotherapy (RT), but in recent years, hedgehog pathway inhibitors (HPIs) have emerged, are effective in more serious cases, and are used primarily or combined with surgery, changing our perspective on the management of these patients. Methods. We studied 24 cases of periocular BCC with orbital invasion, some primary and others recurrent, which were treated between 2011 and 2021 in the same hospital. All patients had clinical or radiological evidence of orbital invasion. Orbital exenteration was performed on 9/24 of the patients (1 received vismodegib after surgery), and 12/24 were treated, surgically preserving the eyeball, with 3 of them receiving adjuvant vismodegib. Three of the twenty-four patients were treated exclusively with vismodegib (Erivedge (R), Genentech). Results. One patient died due to poor tumor evolution, but the rest evolved favorably and they have had no recurrences. Vismodegib was generally well tolerated, except for in one patient who discontinued treatment due to the side effects. Conclusions. In advanced BBC with orbital invasion, mutilating surgical treatments such as exenteration or potentially vision-threatening treatments such as RT remain as options. In recent years, however, very promising new medical therapies have emerged, such as HPI, which can be used effectively instead of surgery or in combination with it, preserving the eye and vision, which implies a new approach to treatment.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Advances in the drug management of basal cell carcinoma
    Ramelyte, Egle
    Restivo, Gaetana
    Mannino, Maria
    Levesque, Mitchell P.
    Dummer, Reinhard
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (05) : 573 - 582
  • [42] Management of periocular basal and squamous cell carcinoma: A series of 485 cases
    Nemet, Arie Y.
    Deckel, Yael
    Martin, Peter A.
    Kourt, Georgina
    Chilov, Michael
    Sharma, Vidushi
    Benger, Ross
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (02) : 293 - 297
  • [43] Update on systemic treatment of basal cell carcinoma
    Stratigos, A. J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 : 16 - 16
  • [44] Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma
    Singalavanija, Tassapol
    Ceylanoglu, Kubra Serbest
    Juntipwong, Sarinee
    Beser, Buse Guneri
    Elner, Victor Maurice
    Worden, Francis Paul
    Demirci, Hakan
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2024, 40 (01): : 1 - 10
  • [45] SOP Standardized Procedure in the Diagnosis and Treatment of periocular Basal Cell Carcinoma
    Kakkassery, Vinodh
    Heindl, Ludwig M.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2018, 235 (01) : 15 - 22
  • [46] Alternative treatment options for periocular basal cell carcinoma: a narrative review
    Erikson, Kristina
    Brosig, Anton
    Zimbelmann, Michael Walter
    Emmert, Steffen
    Guo, Yongwei
    Heindl, Ludwig M.
    Adamietz, Irenaus A.
    Ranjbar, Mahdy
    Grisanti, Salvatore
    Kakkassery, Vinodh
    FRONTIERS OF ORAL AND MAXILLOFACIAL MEDICINE, 2022, 4
  • [47] Advances in Diagnosis and Treatment of Basal Cell Carcinoma
    Khalil, Afrah A.
    Enezei, Hamid H.
    Aldelaimi, Tahrir N.
    Mohammed, Khalil Abdullah
    JOURNAL OF CRANIOFACIAL SURGERY, 2024, 35 (02) : e204 - e208
  • [48] Medial Canthal Contraction as a Marker for Orbital Invasion in Basal Cell Carcinoma
    Juniat, Valerie
    McNab, Alan
    Selva, Dinesh
    OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2021, 37 (3S): : S119 - S120
  • [49] Vismodegib Therapy for Periocular Basal Cell Carcinoma
    Keser, M.
    Green, S.
    Dulz, S.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2017, 234 (01) : 64 - 69
  • [50] Orbital and epidural extension of a locally advanced basal cell carcinoma
    Abrouk, Michael
    Paul, Suchismita
    Abrahams, Jennifer
    Lindsey, Scott
    Tosti, Antonella
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB186 - AB186